Ashley Cordova serves as the Chief Financial Officer (CFO) at NovoCure Ltd., a global oncology company pioneering a novel therapy called Tumor Treating Fields (TTFields) for the treatment of solid tumor cancers. In her role as CFO, Cordova oversees the company's financial operations, including financial planning and analysis, accounting, tax, treasury, and investor relations. Her leadership has been instrumental in guiding NovoCure through significant growth and expansion, particularly as the company continues to develop and commercialize its innovative cancer treatment technologies. Prior to joining NovoCure, Cordova held several high-level financial positions at leading healthcare and biotechnology firms. She spent over a decade at a major pharmaceutical company, where she progressed through various roles in finance and corporate strategy, ultimately serving as the Vice President of Finance. During her tenure, she was recognized for her strategic acumen and ability to drive financial performance, contributing to the successful launch of multiple blockbuster drugs. Cordova's expertise in the life sciences sector, combined with her strong financial background, has made her a valuable asset to NovoCure as the company navigates the complexities of bringing innovative cancer therapies to market. Cordova's achievements extend beyond her professional roles. She is an active member of several industry associations and has been recognized for her contributions to advancing women in finance and leadership within the healthcare sector. Her commitment to mentoring young professionals and promoting diversity and inclusion in the workplace has earned her numerous accolades. At NovoCure, Cordova continues to play a pivotal role in shaping the company's financial strategy, ensuring sustainable growth, and supporting the mission to extend survival in some of the most aggressive forms of cancer.